Dronabinol and chronic pain: importance of mechanistic considerations

Bibliography

• Beaulieu P, Ware M. Reassessment of the role of cannabinoids in the management of pain. Curr Opin Anaesthesiol 2007;20(5):473-7
   PubMed Web of Science ®Google Scholar
• Merskey H, Bogduk N. Classification of chronic pain: descriptions of chronic pain syndromes and definitions of pain terms. 2013. International Association for the Study of Pain (IASP), Task Force on Taxonomy, Seattle 1994
   Google Scholar
• Latremoliere A, Woolf CJ. Central sensitization: a generator of pain hypersensitivity by central neural plasticity. J Pain 2009;10(9):895-926
   PubMed Web of Science ®Google Scholar
• Hashmi JA, Baliki MN, Huang L, et al. Shape shifting pain: chronification of back pain shifts brain representation from nociceptive to emotional circuits. Brain 2013;136(Pt 9):2751-68
   PubMed Web of Science ®Google Scholar
• Mechoulam R, Peters M, Murillo-Rodriguez E, Hanus LO. Cannabidiol – recent advances. Chem Biodivers 2007;4(8):1678-92
   PubMed Web of Science ®Google Scholar
• Thomas A, Baillie GL, Phillips AM, et al. Cannabidiol displays unexpectedly high potency as an antagonist of CB1 and CB2 receptor agonists in vitro. Br J Pharmacol 2007;150(5):613-23
   PubMed Web of Science ®Google Scholar
• Wachtel SR, ElSohly MA, Ross SA, et al. Comparison of the subjective effects of delta(9)-tetrahydrocannabinol and marijuana in humans. Psychopharmacology (Berl) 2002;161(4):331-9
   PubMed Web of Science ®Google Scholar
• Hart CL, Ward AS, Haney M, et al. Comparison of smoked marijuana and oral delta(9)-tetrahydrocannabinol in humans. Psychopharmacology (Berl) 2002;164(4):407-15
   PubMed Web of Science ®Google Scholar
• Russo EB, McPartland JM. Cannabis is more than simply delta(9)-tetrahydrocannabinol. Psychopharmacology (Berl) 2003;165(4):431-2; author reply 433-434
   PubMed Web of Science ®Google Scholar
• Russo EB. Taming THC: potential cannabis synergy and phytocannabinoid-terpenoid entourage effects. Br J Pharmacol 2011;163(7):1344-64
   PubMed Web of Science ®Google Scholar
• Johnson JR, Burnell-Nugent M, Lossignol D, et al. Multicenter, double-blind, randomized, placebo-controlled, parallel-group study of the efficacy, safety, and tolerability of THC:CBD extract and THC extract in patients with intractable cancer-related pain. J Pain Symptom Manage 2010;39(2):167-79
   PubMed Web of Science ®Google Scholar
• Munro S, Thomas KL, Abu-Shaar M. Molecular characterization of a peripheral receptor for cannabinoids. Nature 1993;365(6441):61-5
   PubMed Web of Science ®Google Scholar
• Matsuda LA, Lolait SJ, Brownstein MJ, et al. Structure of a cannabinoid receptor and functional expression of the cloned cDNA. Nature 1990;346(6284):561-4
   PubMed Web of Science ®Google Scholar
• Devane WA, Hanus L, Breuer A, et al. Isolation and structure of a brain constituent that binds to the cannabinoid receptor. Science 1992;258(5090):1946-9
   PubMed Web of Science ®Google Scholar
• Sugiura T, Kondo S, Sukagawa A, et al. 2-Arachidonoylglycerol: a possible endogenous cannabinoid receptor ligand in brain. Biochem Biophys Res Commun 1995;215(1):89-97
   PubMed Web of Science ®Google Scholar
• Hohmann AG, Suplita RL II. Endocannabinoid mechanisms of pain modulation. AAPS J 2006;8(4):E693-708
   Google Scholar
• Pertwee RG. Pharmacology of cannabinoid CB1 and CB2 receptors. Pharmacol Ther 1997;74(2):129-80
   PubMed Web of Science ®Google Scholar
• Pertwee RG. The pharmacology of cannabinoid receptors and their ligands: an overview. Int J Obes (Lond) 2006;30(Suppl 1):S13-18
   PubMed Web of Science ®Google Scholar
• Tsou K, Brown S, Sanudo-Pena MC, et al. Immunohistochemical distribution of cannabinoid CB1 receptors in the rat central nervous system. Neuroscience 1998;83(2):393-411
   PubMed Web of Science ®Google Scholar
• Hohmann AG, Herkenham M. Localization of central cannabinoid CB1 receptor messenger RNA in neuronal subpopulations of rat dorsal root ganglia: a double-label in situ hybridization study. Neuroscience 1999;90(3):923-31
   PubMed Web of Science ®Google Scholar
• Glass M, Dragunow M, Faull RL. Cannabinoid receptors in the human brain: a detailed anatomical and quantitative autoradiographic study in the fetal, neonatal and adult human brain. Neuroscience 1997;77(2):299-318
   PubMed Web of Science ®Google Scholar
• Costa B. On the pharmacological properties of Delta9-tetrahydrocannabinol (THC). Chem Biodivers 2007;4(8):1664-77
   Google Scholar
• Howlett AC. The cannabinoid receptors. Prostaglandins Other Lipid Mediat 2002;68-69:619-31
   PubMed Web of Science ®Google Scholar
• Gong JP, Onaivi ES, Ishiguro H, et al. Cannabinoid CB2 receptors: immunohistochemical localization in rat brain. Brain Res 2006;1071(1):10-23
   PubMed Web of Science ®Google Scholar
• Benito C, Kim WK, Chavarria I, et al. A glial endogenous cannabinoid system is upregulated in the brains of macaques with simian immunodeficiency virus-induced encephalitis. J Neurosci 2005;25(10):2530-6
   Google Scholar
• Benito C, Nunez E, Tolon RM, et al. Cannabinoid CB2 receptors and fatty acid amide hydrolase are selectively overexpressed in neuritic plaque-associated glia in Alzheimer’s disease brains. J Neurosci 2003;23(35):11136-41
   Google Scholar
• Onaivi ES, Ishiguro H, Gu S, Liu QR. CNS effects of CB2 cannabinoid receptors: beyond neuro-immuno-cannabinoid activity. J Psychopharmacol 2012;26(1):92-103
   PubMed Web of Science ®Google Scholar
• Ibrahim MM, Deng H, Zvonok A, et al. Activation of CB2 cannabinoid receptors by AM1241 inhibits experimental neuropathic pain: pain inhibition by receptors not present in the CNS. Proc Natl Acad Sci USA 2003;100(18):10529-33
   PubMed Web of Science ®Google Scholar
• Griffin G, Wray EJ, Tao Q, et al. Evaluation of the cannabinoid CB2 receptor-selective antagonist, SR144528: further evidence for cannabinoid CB2 receptor absence in the rat central nervous system. Eur J Pharmacol 1999;377(1):117-25
   Google Scholar
• Atwood BK, Mackie K. CB2: a cannabinoid receptor with an identity crisis. Br J Pharmacol 2010;160(3):467-79
   PubMed Web of Science ®Google Scholar
• Hohmann AG, Briley EM, Herkenham M. Pre- and postsynaptic distribution of cannabinoid and mu opioid receptors in rat spinal cord. Brain Res 1999;822(1-2):17-25
   PubMed Web of Science ®Google Scholar
• Walker JM, Huang SM, Strangman NM, et al. Pain modulation by release of the endogenous cannabinoid anandamide. Proc Natl Acad Sci USA 1999;96(21):12198-203
   PubMed Web of Science ®Google Scholar
• Ross RA, Coutts AA, McFarlane SM, et al. Actions of cannabinoid receptor ligands on rat cultured sensory neurones: implications for antinociception. Neuropharmacology 2001;40(2):221-32
   Google Scholar
• Lee MC, Ploner M, Wiech K, et al. Amygdala activity contributes to the dissociative effect of cannabis on pain perception. Pain 2013;154(1):124-34
   PubMed Web of Science ®Google Scholar
• Grotenhermen F. Pharmacokinetics and pharmacodynamics of cannabinoids. Clin Pharmacokinet 2003;42(4):327-60
   PubMed Web of Science ®Google Scholar
• Adams IB, Martin BR. Cannabis: pharmacology and toxicology in animals and humans. Addiction 1996;91(11):1585-614
   PubMed Web of Science ®Google Scholar
• Ohlsson A, Lindgren JE, Wahlen A, et al. Plasma delta-9 tetrahydrocannabinol concentrations and clinical effects after oral and intravenous administration and smoking. Clin Pharmacol Ther 1980;28(3):409-16
   PubMed Web of Science ®Google Scholar
• Timpone JG, Wright DJ, Li N, et al. The safety and pharmacokinetics of single-agent and combination therapy with megestrol acetate and dronabinol for the treatment of HIV wasting syndrome. The DATRI 004 Study Group. Division of AIDS Treatment Research Initiative. AIDS Res Hum Retroviruses 1997;13(4):305-15
   PubMed Web of Science ®Google Scholar
• Wall ME, Sadler BM, Brine D, et al. Metabolism, disposition, and kinetics of delta-9-tetrahydrocannabinol in men and women. Clin Pharmacol Ther 1983;34(3):352-63
   PubMed Web of Science ®Google Scholar
• Ashton CH. Pharmacology and effects of cannabis: a brief review. Br J Psychiatry 2001;178:101-6
   PubMed Web of Science ®Google Scholar
• Kelly P, Jones RT. Metabolism of tetrahydrocannabinol in frequent and infrequent marijuana users. J Anal Toxicol 1992;16(4):228-35
   PubMed Web of Science ®Google Scholar
• Matsunaga T, Iwawaki Y, Watanabe K, et al. Metabolism of delta 9-tetrahydrocannabinol by cytochrome P450 isozymes purified from hepatic microsomes of monkeys. Life Sci 1995;56(23-24):2089-95
   PubMed Web of Science ®Google Scholar
• Narimatsu S, Watanabe K, Matsunaga T, et al. Cytochrome P-450 isozymes involved in the oxidative metabolism of delta 9-tetrahydrocannabinol by liver microsomes of adult female rats. Drug Metab Dispos 1992;20(1):79-83
   PubMed Web of Science ®Google Scholar
• Leuschner JT, Harvey DJ, Bullingham RE, Paton WD. Pharmacokinetics of delta 9-tetrahydrocannabinol in rabbits following single or multiple intravenous doses. Drug Metab Dispos 1986;14(2):230-8
   PubMed Web of Science ®Google Scholar
• Stout SM, Cimino NM. Exogenous cannabinoids as substrates, inhibitors, and inducers of human drug metabolizing enzymes: a systematic review. Drug Metab Rev 2014;46(1):86-95
   PubMed Web of Science ®Google Scholar
• Stott C, White L, Wright S, et al. A Phase I, open-label, randomized, crossover study in three parallel groups to evaluate the effect of Rifampicin, Ketoconazole, and Omeprazole on the pharmacokinetics of THC/CBD oromucosal spray in healthy volunteers. Springerplus 2013;2(1):236
   PubMedGoogle Scholar
• Grotenhermen F. The toxicology of cannabis and cannabis prohibition. Chem Biodivers 2007;4(8):1744-69
   PubMed Web of Science ®Google Scholar
• Wang T, Collet JP, Shapiro S, Ware MA. Adverse effects of medical cannabinoids: a systematic review. CMAJ 2008;178(13):1669-78
   PubMed Web of Science ®Google Scholar
• Wade D. Evaluation of the safety and tolerability profile of sativex: is it reassuring enough? Expert Rev Neurother 2012;12(4 Suppl):9-14
   PubMedGoogle Scholar
• Russo EB. Cannabinoids in the management of difficult to treat pain. Ther Clin Risk Manag 2008;4(1):245-59
   PubMedGoogle Scholar
• McQuay HJ, Derry S, Eccleston C, et al. Evidence for analgesic effect in acute pain - 50 years on. Pain 2012;153(7):1364-7
   Google Scholar
• Karst M, Wippermann S, Ahrens J. Role of cannabinoids in the treatment of pain and (painful) spasticity. Drugs 2010;70(18):2409-38
   Google Scholar
• Lynch ME, Campbell F. Cannabinoids for treatment of chronic non-cancer pain; a systematic review of randomized trials. Br J Clin Pharmacol 2011;72(5):735-44
   PubMed Web of Science ®Google Scholar
• Campbell FA, Tramer MR, Carroll D, et al. Are cannabinoids an effective and safe treatment option in the management of pain? A qualitative systematic review. Bmj 2001;323(7303):13-16
   PubMed Web of Science ®Google Scholar
• McCarberg BH, Barkin RL. The future of cannabinoids as analgesic agents: a pharmacologic, pharmacokinetic, and pharmacodynamic overview. Am J Ther 2007;14(5):475-83
   Google Scholar
• Ben Amar M. Cannabinoids in medicine: a review of their therapeutic potential. J Ethnopharmacol 2006;105(1-2):1-25
   PubMed Web of Science ®Google Scholar
• Hazekamp A, Grotenhermen F. Review on clinical studies with cannabis and cannabinoids 2005-2009. Cannabinoids 2010;5(Special issue):1-21
   Google Scholar
• Guindon J, Hohmann AG. The endocannabinoid system and pain. CNS Neurol Disord Drug Targets 2009;8(6):403-21
   PubMed Web of Science ®Google Scholar
• Buggy DJ, Toogood L, Maric S, et al. Lack of analgesic efficacy of oral delta-9-tetrahydrocannabinol in postoperative pain. Pain 2003;106(1-2):169-72
   PubMed Web of Science ®Google Scholar
• Holdcroft A, Maze M, Dore C, et al. A multicenter dose-escalation study of the analgesic and adverse effects of an oral cannabis extract (Cannador) for postoperative pain management. Anesthesiology 2006;104(5):1040-6
   PubMed Web of Science ®Google Scholar
• Pernia-Andrade AJ, Kato A, Witschi R, et al. Spinal endocannabinoids and CB1 receptors mediate C-fiber-induced heterosynaptic pain sensitization. Science 2009;325(5941):760-4
   Google Scholar
• Wallace M, Schulteis G, Atkinson JH, et al. Dose-dependent effects of smoked cannabis on capsaicin-induced pain and hyperalgesia in healthy volunteers. Anesthesiology 2007;107(5):785-96
   PubMed Web of Science ®Google Scholar
• Berman JS, Symonds C, Birch R. Efficacy of two cannabis based medicinal extracts for relief of central neuropathic pain from brachial plexus avulsion: results of a randomised controlled trial. Pain 2004;112(3):299-306
   PubMed Web of Science ®Google Scholar
• Blake DR, Robson P, Ho M, et al. Preliminary assessment of the efficacy, tolerability and safety of a cannabis-based medicine (Sativex) in the treatment of pain caused by rheumatoid arthritis. Rheumatology 2006;45(1):50-2
   PubMed Web of Science ®Google Scholar
• Langford RM, Mares J, Novotna A, et al. A double-blind, randomized, placebo-controlled, parallel-group study of THC/CBD oromucosal spray in combination with the existing treatment regimen, in the relief of central neuropathic pain in patients with multiple sclerosis. J Neurol 2013;260(4):984-97
   PubMed Web of Science ®Google Scholar
• Narang S, Gibson D, Wasan AD, et al. Efficacy of dronabinol as an adjuvant treatment for chronic pain patients on opioid therapy. J Pain 2008;9(3):254-64
   PubMed Web of Science ®Google Scholar
• Notcutt W, Price M, Miller R, et al. Initial experiences with medicinal extracts of cannabis for chronic pain: results from 34 ‘N of 1’ studies. Anaesthesia 2004;59(5):440-52
   PubMed Web of Science ®Google Scholar
• Nurmikko TJ, Serpell MG, Hoggart B, et al. Sativex successfully treats neuropathic pain characterised by allodynia: a randomised, double-blind, placebo-controlled clinical trial. Pain 2007;133(1-3):210-20
   PubMed Web of Science ®Google Scholar
• Rintala DH, Fiess RN, Tan G, et al. Effect of dronabinol on central neuropathic pain after spinal cord injury: a pilot study. Am J Phys Med Rehabil 2010;89(10):840-8
   PubMed Web of Science ®Google Scholar
• Rog DJ, Nurmikko TJ, Friede T, Young CA. Randomized, controlled trial of cannabis-based medicine in central pain in multiple sclerosis. Neurology 2005;65(6):812-19
   PubMed Web of Science ®Google Scholar
• Selvarajah D, Gandhi R, Emery CJ, Tesfaye S. Randomized placebo-controlled double-blind clinical trial of cannabis-based medicinal product (Sativex) in painful diabetic neuropathy: depression is a major confounding factor. Diabetes Care 2010;33(1):128-30
   PubMed Web of Science ®Google Scholar
• Svendsen KB, Jensen TS, Bach FW. Does the cannabinoid dronabinol reduce central pain in multiple sclerosis? Randomised double blind placebo controlled crossover trial. Bmj 2004;329(7460):253
   PubMed Web of Science ®Google Scholar
• Wade DT, Makela P, Robson P, et al. Do cannabis-based medicinal extracts have general or specific effects on symptoms in multiple sclerosis? A double-blind, randomized, placebo-controlled study on 160 patients. Mult Scler 2004;10(4):434-41
   PubMed Web of Science ®Google Scholar
• Wade DT, Robson P, House H, et al. A preliminary controlled study to determine whether whole-plant cannabis extracts can improve intractable neurogenic symptoms. Clin Rehabil 2003;17(1):21-9
   PubMed Web of Science ®Google Scholar
• Zajicek J, Fox P, Sanders H, et al. Cannabinoids for treatment of spasticity and other symptoms related to multiple sclerosis (CAMS study): multicentre randomised placebo-controlled trial. Lancet 2003;362(9395):1517-26
   PubMed Web of Science ®Google Scholar
• Woolf CJ. Central sensitization: implications for the diagnosis and treatment of pain. Pain 2011;152(3 Suppl):S2-15
   PubMed Web of Science ®Google Scholar
• Apkarian AV, Hashmi JA, Baliki MN. Pain and the brain: specificity and plasticity of the brain in clinical chronic pain. Pain 2011;152(3 Suppl):S49-64
   PubMed Web of Science ®Google Scholar
• Yarnitsky D. Conditioned pain modulation (the diffuse noxious inhibitory control-like effect): its relevance for acute and chronic pain states. Curr Opin Anaesthesiol 2010;23(5):611-15
   PubMed Web of Science ®Google Scholar
• Lesko LJ. Personalized medicine: elusive dream or imminent reality? Clin Pharmacol Ther 2007;81(6):807-16
   PubMed Web of Science ®Google Scholar
• Bruehl S, Apkarian AV, Ballantyne JC, et al. Personalized medicine and opioid analgesic prescribing for chronic pain: opportunities and challenges. J Pain 2013;14(2):103-13
   PubMed Web of Science ®Google Scholar
• Olesen SS, Graversen C, Bouwense SA, et al. Quantitative sensory testing predicts pregabalin efficacy in painful chronic pancreatitis. PLoS One 2013;8(3):e57963
   PubMed Web of Science ®Google Scholar
• Yarnitsky D, Granot M, Nahman-Averbuch H, et al. Conditioned pain modulation predicts duloxetine efficacy in painful diabetic neuropathy. Pain 2012;153(6):1193-8
   PubMed Web of Science ®Google Scholar
• Edwards RR, Haythornthwaite JA, Tella P, et al. Basal heat pain thresholds predict opioid analgesia in patients with posttherpetic neuralgia. Anesthesiology 2006;104(6):1243-8
   PubMed Web of Science ®Google Scholar
• Hansson P, Backonja M, Bouhassira D. Usefulness and limitations of quantitative sensory testing: clinical and research application in neuropathic pain states. Pain 2007;129(3):256-9
   Google Scholar
• Bouwense SA, Olesen SS, Drewes AM, et al. Effects of pregabalin on central sensitization in patients with chronic pancreatitis in a randomized, controlled trial. PLoS One 2012;7(8):e42096
   PubMed Web of Science ®Google Scholar
• Graversen C, Olesen SS, Olesen AE, et al. The analgesic effect of pregabalin in patients with chronic pain is reflected by changes in pharmaco-EEG spectral indices. Br J Clin Pharmacol Ther 2012;73(3):363-72
   Google Scholar
• Noble M, Tregear SJ, Treadwell JR, Schoelles K. Long-term opioid therapy for chronic noncancer pain: a systematic review and meta-analysis of efficacy and safety. J Pain Symptom Manage 2008;35(2):214-28
   PubMed Web of Science ®Google Scholar
• Brush DE. Complications of long-term opioid therapy for management of chronic pain: the paradox of opioid-induced hyperalgesia. J Med Toxicol 2012;8(4):387-92
   PubMedGoogle Scholar
• Angst MS, Clark JD. Opioid-induced hyperalgesia: a qualitative systematic review. Anesthesiology 2006;104(3):570-87
   PubMed Web of Science ®Google Scholar
• Chaparro LE, Wiffen PJ, Moore RA, Gilron I. Combination pharmacotherapy for the treatment of neuropathic pain in adults. Cochrane Database Syst Rev 2012;7:CD008943
   PubMed Web of Science ®Google Scholar
• Gilron I, Max MB. Combination pharmacotherapy for neuropathic pain: current evidence and future directions. Expert Rev Neurother 2005;5(6):823-30
   PubMedGoogle Scholar
• Cichewicz DL. Synergistic interactions between cannabinoid and opioid analgesics. Life Sci 2004;74(11):1317-24
   PubMed Web of Science ®Google Scholar
• Desroches J, Beaulieu P. Opioids and cannabinoids interactions: involvement in pain management. Curr Drug Targets 2010;11(4):462-73
   PubMed Web of Science ®Google Scholar
• Cichewicz DL, Welch SP. Modulation of oral morphine antinociceptive tolerance and naloxone-precipitated withdrawal signs by oral delta 9-tetrahydrocannabinol. J Pharmacol Exp Ther 2003;305(3):812-17
   PubMed Web of Science ®Google Scholar
• Cichewicz DL, McCarthy EA. Antinociceptive synergy between delta(9)-tetrahydrocannabinol and opioids after oral administration. J Pharmacol Exp Ther 2003;304(3):1010-15
   PubMed Web of Science ®Google Scholar
• Pugh G Jr, Smith PB, Dombrowski DS, Welch SP. The role of endogenous opioids in enhancing the antinociception produced by the combination of delta 9-tetrahydrocannabinol and morphine in the spinal cord. J Pharmacol Exp Ther 1996;279(2):608-16
   PubMed Web of Science ®Google Scholar
• Welch SP, Eads M. Synergistic interactions of endogenous opioids and cannabinoid systems. Brain Res 1999;848(1-2):183-90
   PubMed Web of Science ®Google Scholar
• Welch SP, Stevens DL. Antinociceptive activity of intrathecally administered cannabinoids alone, and in combination with morphine, in mice. J Pharmacol Exp Ther 1992;262(1):10-18
   Google Scholar
• Welch SP, Thomas C, Patrick GS. Modulation of cannabinoid-induced antinociception after intracerebroventricular versus intrathecal administration to mice: possible mechanisms for interaction with morphine. J Pharmacol Exp Ther 1995;272(1):310-21
   Google Scholar
• Pugh G Jr, Welch SP, Bass PP. Modulation of free intracellular calcium and cAMP by morphine and cannabinoids, alone and in combination in mouse brain and spinal cord synaptosomes. Pharmacol Biochem Behav 1994;49(4):1093-100
   Google Scholar
• Roberts JD, Gennings C, Shih M. Synergistic affective analgesic interaction between delta-9-tetrahydrocannabinol and morphine. Eur J Pharmacol 2006;530(1-2):54-8
   PubMed Web of Science ®Google Scholar